SUPPRESSIVE LONG-TERM ANTIVIRAL MGMT OF HCV & HIV-1 COINFECTED SUBJECTS (SLAM-C)

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这是一项针对丙型肝炎病毒和HIV-1混合感染患者的抑制性、长期、抗病毒维持疗法的II期开放标签双臂研究。这项试验旨在研究长期服用聚乙二醇化干扰素α-2a(聚乙二醇化干扰素-2a)是否能降低在聚乙二醇化干扰素加利巴韦林治疗期间未能达到或将丙型肝炎病毒载量维持在检测极限以下的丙型肝炎病毒/艾滋病毒混合感染者的肝纤维化进展速度。接受丙型肝炎病毒治疗的新受试者和先前接受治疗的受试者都将被纳入研究。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a phase II, open-label, two-arm study of suppressive, long-term, antiviral maintenance therapy for hepatitis C virus and HIV-1 co-infected patients. This trial is designed to study whether long-term maintenance with pegylated-interferon alfa-2a (PEG-IFN) reduces the rate of liver fibrosis progression in subjects with HCV/HIV co-infection who have failed to achieve or maintain HCV loads below the limit of detection during treatment with PEG-IFN plus ribavirin. Both HCV treatment na¿ve and previously treated subjects will be enrolled.